Last reviewed · How we verify
ROTAVAC 5C -F1
ROTAVAC 5C-F1 is a live attenuated rotavirus vaccine that stimulates immune responses against rotavirus to prevent gastroenteritis.
ROTAVAC 5C-F1 is a live attenuated rotavirus vaccine that stimulates immune responses against rotavirus to prevent gastroenteritis. Used for Prevention of rotavirus gastroenteritis in infants and young children.
At a glance
| Generic name | ROTAVAC 5C -F1 |
|---|---|
| Sponsor | Bharat Biotech International Limited |
| Drug class | Live attenuated rotavirus vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This is a pentavalent rotavirus vaccine candidate developed by Bharat Biotech containing five rotavirus strains (G1, G2, G3, G4, and G9). It works by introducing weakened rotavirus particles that trigger both humoral and mucosal immune responses, enabling the body to recognize and neutralize wild-type rotavirus before infection occurs. The vaccine is designed to provide broad protection against the most clinically relevant rotavirus genotypes.
Approved indications
- Prevention of rotavirus gastroenteritis in infants and young children
Common side effects
- Diarrhea
- Vomiting
- Fever
- Irritability
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ROTAVAC 5C -F1 CI brief — competitive landscape report
- ROTAVAC 5C -F1 updates RSS · CI watch RSS
- Bharat Biotech International Limited portfolio CI